The TIM Digest: Newsletter Q1
May, 2025 –
In this first edition, we’re sharing some exciting new publications, upcoming events for Q2, and introducing a new team member. We are excited to keep you up to date on all things TIM and beyond!
With the first quarter of 2025 wrapped up, we’re off to a great start—6 new peer-reviewed studies featuring TIM models have been published, bringing the total track record to 365! In this first edition, we’re sharing some exciting new publications, upcoming events for Q2, and introducing a new team member. We are excited to keep you up to date on all things TIM and beyond!
- Read the most recent scientific papers featuring TIM®
- Find out where you can meet the InnoGI team next in the upcoming events of Q2
- Get to know Jeroen Kiers, new to the team as Managing Director
- All about TIM-2muc and also a vacancy for Senior Business Development manager (update: vacancy filled)
Recent Scientific Publications
1. Investigating the ROS Formation and Particle Behavior of Food-Grade Titanium Dioxide (E171) in the TIM-1:
The TIM-1 model helped clarify the safety of food additives in risk assessment.
Bischoff et al., 2025 University Maastricht
Key words: TIM-1, Food Additive, Food Safety, TIM Upper GI
2. Postbiotic potential of Lactococcus lactis in alleviating visceral pain in female rat through GABA production:
TIM-1 can contribute to unraveling the mechanism of action underlying physiological effects of pro- and postbiotics in the gut-brain axis.
Gomes et al., 2025, Lesaffre
key words: TIM-1, Probiotics, TIM Upper GI
3. In vitro human gastrointestinal digestibility and colonic fermentation of edible yeast-based protein:
Digestibility of yeast-based protein as alternative protein source assessed in TIM-1.
Caron et al., 2025, Lesaffre
Key words: TIM-1, Proteins, Digestibility, TIM Upper GI
4. Assessing the Impacts of Drug Loading and Polymer Type on Dissolution Behavior and Diffusive Flux of GDC-6893 ASDs :Tiny-TIM advances drug development by assessing the in vitro performance of ASDs with varying drug loads.
Shetty et al., 2025, Genentech
key words: tiny-TIM, ASD, TIM Upper GI
5. The potential of fermented beetroot ketchup: Enhancing polyphenol recovery and gut microbiota interactions
The TIM-2 model demonstrates its usefulness in advancing food product development, including ketchup.
Kücükgoz & Venema et al., 2025, University Warsaw, Wageningen
Key words: TIM-2, Food, Nutrition, TIM Colon, Large Intestine
6. Assessing the potential for non-digestible carbohydrates towards mitigating adverse effects of antibiotics on microbiota composition and activity in an in vitro colon model of the weaning infant With ethical constraints on in vivo infant studies, TIM-2 can explore microbiota changes from antibiotics and resilience to probiotics.
Endika et al., 2025, MUMC, Wageningen University
Keywords: TIM-2; Food; infant, colon, Lower GI, Microbiota
Meet the InnoGI team at upcoming events!
With the first event of Q2 — Innovation for Health — already behind us, the second quarter of 2025 is packed with exciting opportunities to meet, connect, and discuss GI modeling!
We are looking forward discuss how our dynamic in vitro GI models like the TIM-1 and TIM-2 accurately mimic the GI tract and help you to better understand how oral pharmaceutical and nutritional products behave in the gut — from drug delivery to microbiome modulation.
Here’s where you can find InnoGI Technologies and our team:
- Microbiome & Probiotics R&D and Business collaboration forum – April 28-29, The Hague, NL
- DDF Global Summit– June 2-4, Berlin, DE
- BIO US – June 16-19, Boston US
- Discovery & Development – June 23-24, Basel, CH
- Dutch Biotech Event – June 27, Maarsen, NL
- and more to come….!
Attending one of these events? We’d love to meet for a coffee or a chat – reach out to schedule a meeting!
NEW! TIM Colon Mucus Addition!
We released our TIM-2mucus model at the Microbiome Movement Summit this Januari and shared some exclusive insights into our cutting-edge TIM-2muc model and its groundbreaking potential for gut microbiome research.
Missed the presentation at the Microbiome movement? Our TIM-2 expert is happy to tell you all about it!
InnoGI introduces…..
Get to know InnoGI! Each quarter, we’ll introduce you to one of our team members. This edition, meet our newest team member, Jeroen Kiers, PhD as Managing Director!
Dear TIM fans,
Happy to meet you! I am thrilled to join the team at InnoGI to strengthen and expand our operational and commercial CRO capabilities. I have been in the industry for more than 25 years in various roles ranging from R&D to business management across corporates, SMEs, and start-ups, and am especially fond to mention I have used TIM technology quite a lot in my career.
At InnoGI, I look forward to continue to advance GI-modelling to serve our customers in sustainable oral drug and nutritional research and development!
Kind regards,
Jeroen Kiers, PhD
Follow your gut feeling! Join InnoGI
[UPDATE] THE POSITION IS FILLED.
We are looking for a Sr. Business development manager!
we are on a mission to improve oral drug and food product development with our cutting-edge TIM Technology, accurately mimicking the gastrointestinal tract — and we’re looking for a Senior Business Development Manager to help us take our innovations global.
A great opportunity to work with innovative technology, a passionate team, and make real impact! and best of all daily walks in nature!
Are you experienced in driving growth, building partnerships, and translating complex science into real-world value? Then Trust your Gut — Join the InnoGI Team here!
Get in contact
We are excited to hear what’s on your plate and how we can help you understand what happens to your product during digestion!
